Get the Stockscreener App
10.03
5.80%
0.55
Biohaven Ltd stock is traded at $10.03, with a volume of 1.75M.
It is up +5.80% in the last 24 hours and down -41.69% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$9.48
Open:
$9.66
24h Volume:
1.75M
Relative Volume:
0.49
Market Cap:
$1.06B
Revenue:
-
Net Income/Loss:
$-766.97M
P/E Ratio:
-1.3094
EPS:
-7.66
Net Cash Flow:
$-646.43M
1W Performance:
+3.51%
1M Performance:
-41.69%
6M Performance:
-33.40%
1Y Performance:
-78.37%
1-Day Range:
$9.5645
$10.18
1-Week Range:
$8.92
$10.18
52-Week Range:
$7.48
$47.42
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
10.03 | 1.26B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost - Yahoo! Finance Canada
Why Biohaven Ltd. Common Shares stock is a strong analyst pickCEO Change & Free Expert Verified Stock Movement Alerts - moha.gov.vn
The Bull Case For Biohaven (BHVN) Could Change Following Recent Analyst Downgrades - simplywall.st
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy? - AOL.com
Can Biohaven Ltd. stock outperform in 2025 bull market2025 Market WrapUp & Long Hold Capital Preservation Plans - moha.gov.vn
Biohaven downgraded to Neutral from Buy at UBS - MSN
Understanding the Setup: (BHVN) and Scalable Risk - news.stocktradersdaily.com
UBS Downgrades Biohaven (BHVN) and Lowers Price Target | BHVN St - GuruFocus
UBS downgrades Biohaven stock to Neutral on pipeline setbacks By Investing.com - Investing.com South Africa
UBS Downgrades Biohaven to Neutral From Buy, $11 Price Target - MarketScreener
Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges - TipRanks
UBS downgrades Biohaven stock to Neutral on pipeline setbacks - Investing.com
Jim Cramer on Biohaven: “The Stock Seems Very Low to Me” - MSN
Jim Cramer on Biohaven: "The Stock Seems Very Low to Me" - Finviz
Assessing Biohaven (BHVN) Valuation Following $175 Million Equity Offering and Underwriter Changes - simplywall.st
A Crucial Secondary Offering At Biohaven – Insider Weekends (NYSE:BHVN) - Seeking Alpha
Biohaven Ltd. Reports Q3 2025 Financial Results - MSN
Will Biohaven's (BHVN) $175 Million Equity Raise Reshape Its Path to Financial Strength? - simplywall.st
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth - MSN
Is Biohaven Ltd. Common Shares stock undervalued historically2025 Performance Recap & Stepwise Trade Execution Plans - newser.com
Biohaven Insiders Bet $33 Million on a Turnaround - MarketBeat
Biohaven price target lowered to $15 from $47 at JPMorgan - TipRanks
How Biohaven Ltd. stock reacts to inflationary pressuresJuly 2025 Market Mood & Target Return Focused Picks - newser.com
Should I buy Biohaven Ltd. Common Shares stock before earnings season2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
How Biohaven Ltd. stock benefits from global expansionAnalyst Upgrade & Technical Pattern Based Signals - newser.com
Can Biohaven Ltd. Common Shares stock sustain double digit ROEJuly 2025 Fed Impact & AI Driven Price Forecasts - newser.com
Is Biohaven Ltd. stock vulnerable to regulatory risks2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
Why hedge funds are buying Biohaven Ltd. stockQuarterly Portfolio Review & High Conviction Trade Alerts - newser.com
What MACD trends signal for Biohaven Ltd. Common Shares stockPortfolio Profit Report & High Win Rate Trade Alerts - newser.com
What Fibonacci levels say about Biohaven Ltd. reboundWeekly Loss Report & Free Long-Term Investment Growth Plans - newser.com
Building trade automation scripts for Biohaven Ltd.2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Why Biohaven Ltd. stock is favored by pension fundsQuarterly Performance Summary & Fast Moving Market Watchlists - newser.com
Signal strength of Biohaven Ltd. stock in tech scanners2025 Top Gainers & Risk Controlled Daily Trade Plans - newser.com
Can Biohaven Ltd. stock resist sector downturnsJuly 2025 Recap & Pattern Based Trade Signal System - newser.com
Has Biohaven Ltd. formed a bullish divergenceJuly 2025 Chart Watch & Low Drawdown Investment Ideas - newser.com
Market reaction to Biohaven Ltd.’s recent newsQuarterly Trade Review & Free Accurate Trade Setup Notifications - newser.com
Independent Director of Biohaven John Childs Buys 52% More Shares - simplywall.st
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):